# Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

> **NCT02402660** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Alkeus Pharmaceuticals, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

## Interventions

- **DRUG:** ALK-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02402660
- **Lead sponsor:** Alkeus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2015-08
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402660, "Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02402660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*